ada glp 1 recommendations John Buse Lesson: Oral Semaglutide: A New

Dupixent (dupilumab) Disease area(s): Immunology/respiratory Manufacturer(s): Sanofi/Regeneron 2024 Sales (USD): $14.15 billion Why it sold so well: Co-developed by Sanofi and Regeneron, Dupixent achieved significant success in 2024, with global net sales reaching $14.15 billion a 22% increase over 2023

However, the certification does not test for allulose itself, meaning certified products may still cause digestive upset

However, the general principle of watching the retina during rapid glucose improvement applies more broadly

Patients on GLP-1 drugs tend to have EWDR for one to two years after rapid A1c improvement